Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CDH6-ADC
- Development stage
- Preclinical
- Lead developer
- Novartis
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CDH6-ADC is an antibody-drug conjugate (ADC) consisting of a fully human IgG1 monoclonal antibody targeting Cadherin-6 (CDH6), conjugated to the tubulin-binding maytansinoid payload DM4 (ravtansine) via a cleavable sulfo-SPDB linker. CDH6 is a cell adhesion molecule frequently overexpressed in ovarian and renal cell carcinomas, while maintaining restricted expression in normal tissues. Upon binding to CDH6 on the tumor cell surface, the ADC is internalized, and the DM4 payload is released to inhibit microtubule assembly, leading to cell cycle arrest and apoptosis. Developed by Novartis, CDH6-ADC has demonstrated robust anti-tumor activity in patient-derived xenograft (PDX) models of ovarian and renal cancer, including those refractory to standard-of-care chemotherapy.
- Other names
- anti-CDH6 ADCanti-CDH-6 ADCanti-CDH 6 ADCCDH6-sulfo-SPDB-DM4CDH-6-sulfo-SPDB-DM4CDH 6-sulfo-SPDB-DM4CHD6-ADCCHD-6-ADCCHD 6-ADC
02
Targets
TUBB (Tubulin (alpha and beta subunits))CDH6 (Cadherin-6)
Beyond the preview
Go deeper on CDH6-ADC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CDH6-ADC.